Prosecution Insights
Last updated: October 23, 2026
Application No. 18/267,827

MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES

Non-Final OA §112
Filed
Jun 16, 2023
Priority
Dec 18, 2020 — provisional 63/127,852 +2 more
Examiner
MCINTOSH III, TRAVISS C
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Compass Pathfinder Limited
OA Round
3 (Non-Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
983 granted / 1341 resolved
+13.3% vs TC avg
Moderate +14% lift
Without
With
+14.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
31 currently pending
Career history
1376
Total Applications
across all art units

Statute-Specific Performance

§101
6.2%
-33.8% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
23.3%
-16.7% vs TC avg
§112
31.9%
-8.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1341 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/1/26 has been entered. The Amendment filed 9/1/26 has been received, entered into the record, and carefully considered. The following information provided in the amendment affects the instant application by: Claims 1, 11, 13-16, 21, and 67 have been amended. No claims have been added. Claims 22-66 have been canceled. Remarks drawn to rejections of Office Action mailed 6/1/26 include: 112 2nd paragraph rejections: which have been overcome by applicant’s amendments and have been withdrawn. 102(a)(2) rejection: which have been overcome by applicant’s amendments and have been withdrawn. 103(a) rejection: which have been overcome by applicant’s amendments and have been withdrawn. An action on the merits of claims 1-22 and 67 is contained herein below. The text of those sections of Title 35, US Code which are not included in this action can be found in a prior Office action. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-12 and 16-22 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 provides that R4, R5, R6, and R7 are optionally “X”, however there is no definition for X as X was deleted in the claim amendment filed 9/1/26 and thus it is unclear the scope and metes and bounds of the claim. Removing the “X” from the definition and putting the “or” before “-Q” would overcome this rejection. All claims which depend from an indefinite claim are also indefinite. Ex parte Cordova, 10 U.S.P.Q. 2d 1949, 1952 (P.T.O. Bd. App. 1989). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 67 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 67 provides the compound of claim1 is optionally PNG media_image1.png 90 166 media_image1.png Greyscale which would require R9, R10 and R2 to join and form a ring system, which is not embraced by the variables and definitions of claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 13-15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached Monday-Friday 9AM-5:30PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TRAVISS C MCINTOSH III/ Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
Sep 25, 2025
Non-Final Rejection mailed — §112
Feb 17, 2026
Response Filed
Jun 01, 2026
Final Rejection mailed — §112
Sep 01, 2026
Request for Continued Examination
Sep 05, 2026
Response after Non-Final Action
Sep 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767617
Green Methods of Carbohydrate Acetylation
4y 0m to grant Granted Oct 20, 2026
Patent 12766160
COMPOSITION COMPRISING POLYGALATENOSIDE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER
2y 6m to grant Granted Oct 20, 2026
Patent 12760125
METHOD FOR PREPARING RESISTANT DEXTRIN
2y 9m to grant Granted Oct 13, 2026
Patent 12741949
AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME
3y 2m to grant Granted Sep 22, 2026
Patent 12741984
NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS
2y 3m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
87%
With Interview (+14.1%)
2y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1341 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month